Effect of Topical Nepafenac on Central Foveal Thickness following Panretinal Photocoagulation in Diabetic Patients

Table 1

Baseline characteristics of studied patients.

	Nepafenac group ()	Control group ()	value
Age (years) mean ± SD	47.6 ± 6.3	46.4 ± 5.6	0.91
Female sex, n (%)	16 (53.3%)	18 (60%)	0.89
Type of diabetes, n (%)
Type I	11 (36.7%)	10 (33.3%)	0.82
Type II	16 (53.3%)	18 (60%)
Uncertain	3 (10%)	2 (6.7%)
Duration of diabetes (years) mean ± SD	9.3 ± 2.9	9.5 ± 2.7	0.87
Hypertension, n (%)	18 (60%)	17 (56.7%)	1.00
HBA1c (%) mean ± SD	8.1 ± 1.1	8.2 ± 1.2	0.88
Type of diabetic retinopathy
Severe NPDR	9 eyes (30%)	11 eyes (36.7%)	0.87
PDR	21 eyes (70%)	19 eyes (63.3%)	0.89

NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; SD: standard deviation.